Thalassemia in Sri Lanka

dc.contributor.authorPremawardhena, A.P.
dc.contributor.authorMadushanka, H.D.P.
dc.date.accessioned2022-08-17T06:32:34Z
dc.date.available2022-08-17T06:32:34Z
dc.date.issued2022
dc.descriptionIndexed in MEDLINE.en_US
dc.description.abstractThe island nation of Sri Lanka with 22 million people (in 2020) has an estimated 2000 patients with severe thalassemia. The majority have β-thalassemia (β-thal) major (β-TM), and Hb E (HBB: c.79G>A)/β-thal accounts for most of the remainder. Carrier rate for α+-thalassemia (α+-thal) trait is 9.9% and β-thal trait is 2.5%, with very similar rates in the three major ethnic groups (Sinhalese, Tamils and Moors). The distribution of thalassemia type reveals a remarkable variation, even in this small island, mirroring historical distribution of malaria. Even though healthcare is provided free by the state including blood transfusions and chelation, the overall survival of patients of β-TM is still not on a par with that of the Mediterranean countries. A national thalassemia prevention program was set up in 2007, but overall success of the exercise based essentially on dissuasion of marriages is not very promising.en_US
dc.identifier.citationHemoglobin.2022;46(1):71-73.en_US
dc.identifier.issn0363-0269
dc.identifier.urihttp://repository.kln.ac.lk/handle/123456789/25079
dc.language.isoenen_US
dc.publisherInforma Healthcare,Londonen_US
dc.subjectHemoglobinopathyen_US
dc.subjectSouth Asiaen_US
dc.subjectSri Lankaen_US
dc.titleThalassemia in Sri Lankaen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
52 B
Format:
Item-specific license agreed upon to submission
Description: